NF-kappaB Pathway Inhibitors Preferentially Inhibit Breast Cancer Stem-like Cells

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2007 Oct 30

PMID 17965935

Citations 87

Authors

Jiangbing Zhou

Hao Zhang

Peihua Gu

Jining Bai

Joseph B Margolick

Ying Zhang

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence indicates that breast cancer is caused by cancer stem cells and cure of breast cancer requires eradication of breast cancer stem cells. Previous studies with leukemia stem cells have shown that NF-kappaB pathway is important for leukemia stem cell survival. In this study, by using MCF7 sphere cells as model of breast cancer stem-like cells, we evaluated the effect of NF-kappaB pathway specific inhibitors on human breast cancer MCF7 sphere cells. Three inhibitors including parthenolide (PTL), pyrrolidinedithiocarbamate (PDTC) and its analog diethyldithiocarbamate (DETC) were found to preferentially inhibit MCF7 sphere cell proliferation. These compounds also showed preferential inhibition in term of proliferation and colony formation on MCF7 side population (SP) cells, a small fraction of MCF7 cells known to enrich in breast cancer stem-like cells. The preferential inhibition effect of these compounds was due to inhibition of the NF-kappaB activity in both MCF7 sphere and MCF7 cells, with higher inhibition effect on MCF7 sphere cells than on MCF7 cells. PDTC was further evaluated in vivo and showed significant tumor growth inhibition alone but had better tumor growth inhibition in combination with paclitaxel in the mouse xenograft model than either PDTC or paclitaxel alone. This study suggests that breast cancer stem-like cells could be selectively inhibited by targeting signaling pathways important for breast cancer stem-like cells.

Citing Articles

Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.

Ali K, Nabeel M, Mohsin F, Iqtedar M, Islam M, Rasool M Med Oncol. 2024; 41(5):112.

PMID: 38592510 DOI: 10.1007/s12032-024-02347-z.

Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide.

Lapcik P, Sulc P, Janacova L, Jilkova K, Potesil D, Bouchalova P Cell Mol Biol Lett. 2023; 28(1):68.

PMID: 37620794 PMC: 10464112. DOI: 10.1186/s11658-023-00481-6.

Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications.

Ordaz-Ramos A, Tellez-Jimenez O, Vazquez-Santillan K Front Cell Dev Biol. 2023; 11:1221175.

PMID: 37492224 PMC: 10363614. DOI: 10.3389/fcell.2023.1221175.

Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.

Lucic I, Kurtovic M, Mlinaric M, Pitesa N, cipak Gasparovic A, Sabol M Int J Mol Sci. 2023; 24(13).

PMID: 37445860 PMC: 10342190. DOI: 10.3390/ijms241310683.

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces.

Safa A Cancer Drug Resist. 2023; 5(4):850-872.

PMID: 36627897 PMC: 9771762. DOI: 10.20517/cdr.2022.20.

References

Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y . Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 2006; 7(6):R1097-110. PMC: 1410757. DOI: 10.1186/bcr1344. View

Singh S, Aggarwal B . Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42):24995-5000. DOI: 10.1074/jbc.270.42.24995. View

Zhou S, Schuetz J, Bunting K, Colapietro A, Sampath J, Morris J . The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7(9):1028-34. DOI: 10.1038/nm0901-1028. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

Graham S, Jorgensen H, Allan E, Pearson C, Alcorn M, Richmond L . Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99(1):319-25. DOI: 10.1182/blood.v99.1.319. View

Weissman I . Stem cell research: paths to cancer therapies and regenerative medicine. JAMA. 2005; 294(11):1359-66. DOI: 10.1001/jama.294.11.1359. View

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

Behbod F, Rosen J . Will cancer stem cells provide new therapeutic targets?. Carcinogenesis. 2004; 26(4):703-11. DOI: 10.1093/carcin/bgh293. View

Peng Y, Power M, Li B, Lin T . Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation. J Leukoc Biol. 2005; 77(6):975-83. DOI: 10.1189/jlb.0204115. View

10.

Xu Q, Simpson S, Scialla T, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102(3):972-80. DOI: 10.1182/blood-2002-11-3429. View

11.

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

12.

Polyak K, Hahn W . Roots and stems: stem cells in cancer. Nat Med. 2006; 12(3):296-300. DOI: 10.1038/nm1379. View

13.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

14.

Goodell M, Rosenzweig M, Kim H, Marks D, Demaria M, Paradis G . Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997; 3(12):1337-45. DOI: 10.1038/nm1297-1337. View

15.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

16.

Weber C, Liptay S, Wirth T, Adler G, Schmid R . Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000; 119(5):1209-18. DOI: 10.1053/gast.2000.19458. View

17.

Zhang M, Rosen J . Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2005; 16(1):60-4. DOI: 10.1016/j.gde.2005.12.008. View

18.

Garcia-Pineres A, Castro V, Mora G, Schmidt T, Strunck E, Pahl H . Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem. 2001; 276(43):39713-20. DOI: 10.1074/jbc.M101985200. View

19.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

20.

Al-Hajj M, Becker M, Wicha M, Weissman I, Clarke M . Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004; 14(1):43-7. DOI: 10.1016/j.gde.2003.11.007. View